Q3 2025 Nektar Therapeutics Earnings Call Transcript

Nov 6, 2025 / 10:00 PM GMT

Release Date Price: €46.4 (-2.52%)

Transcript 10-Q8-K

Key Points

Positve

Nektar Therapeutics (NKTR) has a strong cash position with $270.2 million in cash and investments and no debt, extending their cash runway into the second quarter of 2027.
The company presented compelling results from their 16-week induction period of the 400 patient Resolve AD study of ResPEG in moderate to severe atopic dermatitis, showcasing clinical differentiation.
Nektar Therapeutics (NKTR) plans to present topline results from the phase 2B Resolve AA study in patients with alopecia areata in December, representing a potential $1 billion market opportunity.
The company is advancing its lead program, ResPEG aldeleukin, into phase 3 development, focusing on stimulating T regulatory cells to restore immune system balance.
Nektar Therapeutics (NKTR) has received recognition for its work on ResPEG, with the Nobel Prize in Physiology or Medicine highlighting the importance of T regulatory cells in immune tolerance.

Negative

Nektar Therapeutics (NKTR) faces uncertainties and risks associated with forward-looking statements, which may result in actual results differing materially.
The company has a net loss for the third quarter of $35.5 million or $1.87 basic and diluted net loss per share.
There are concerns about the limited treatment options for severe to very severe alopecia areata, with current FDA-approved treatments being JAK inhibitors that carry black box warnings.
Nektar Therapeutics (NKTR) does not currently plan to pursue an asthma indication, despite the potential benefits of ResPEG for patients with both atopic dermatitis and asthma.
The company has yet to see a plateau in the efficacy response in the ResPEG treatment arms, indicating ongoing challenges in achieving optimal treatment outcomes.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NKTR.OQ - Nektar Therapeutics
Q3 2025 Nektar Therapeutics Earnings Call
Nov 06, 2025 / 10:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and thank you for standing by. Welcome to the Nectar Therapeutics 3rd quarter 2025 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Vivian Wu from Nectar Investor Relations to kick things off. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Crystal, and good afternoon, everyone.

Thank you for joining us today.

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.